The Associated Press reports that in the wake of President Obama’s decision to push for a shorter period of exclusivity for biologics, the drug lobby is threatening to walk away from its deal to support the bill:
It was a surprise indeed. Most people had figured that the biologic drug industry had sealed the deal for 12 years of protection from generic competition when it succeeded in getting language to that effect in both the House and Senate health care bills. Although President Obama had supported shorter protection of seven years,* there had …
A while back, Michael Scherer and I wrote this story about how the biotech industry has been one of the big winners in the health care debate.
Maybe not so much, it now appears. The New York Times reports that President Obama may be making a last stand to bring lower-cost generic biologics to market more quickly: